# Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin

> **NCT00397904** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Esophageal Cancer
- Gastric Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** cisplatin
- **DRUG:** irinotecan hydrochloride
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT00397904
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2015-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00397904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00397904, "Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00397904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*